Maurya, Gupta, Verma, Singh, Singh, Singh, Roy, Mehla, and Kumar: Sex hormones and dry eye disease: Current update


Introduction

According to international Dry Eye Workshop (DEWS) report in 2007, Dry eye disease (DED) is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.1 It is one of the most common complaints in ophthalmic practice. Common symptoms of DED include foreign body sensation, grittiness, itching, burning, stinging, tearing, photophobia, fluctuating or blurry vision, leading to ocular discomfort and reduced visual acuity which significantly affects the quality of life of patients.2, 3, 4, 5 Peri and post-menopausal women, elderly, contact lens wearers, those exposed to environmental and occupational factors, patients after refractive surgery, suffering from autoimmune diseases or under some topical or systemic therapies are more prone to dry eye disease.6 The prevalence of DED ranges from 7.8% to 33.7%, depending on population being studied and assessment methods used.7 A study in United States showed that the prevalence of DED in women over 50 years is 7% and in men over 50 years is 4%, nearly half of that in women.8, 9 Other studies also showed that women has greater frequency and severity of DED than men, that’s why women’s well-being is much more affected by DED.10 The frequency of DED increases with increasing age in both men and women and postmenopausal women are at higher risk of developing DED than younger women and men.11

Pathophysiology of Dry eye Disease

A preocular tear film is important for maintaining a smooth refractive corneal surface for optimal vision. 12, 13 Dry eye occurs when the tear film is disturbed as a result of decreased tear production or increased tear evaporation. 14 A normal tear film has three layers: inner hydrophilic mucin layer is mainly produced by conjunctival goblet cells and also by glycocalyx of the superficial layers of conjunctival and corneal epithelial cells, middle aqueous layer is produced by main and accessory lacrimal glands and outer lipid layer is secreted by meibomian glands (modified sebaceous glands). An integrated neural reflex loop (sensorimotor) balances aqueous production and tear evaporation thus maintaining normal tear film.15 Ocular surface system (OSS) or lacrimal functional unit comprises of corneal epithelium, conjunctival epithelium with goblet cells, limbal stem cells that maintains epithelial turnover, tear film that keeps ocular surface moist and lubricated, main and accessory lacrimal glands, meibomian glands, eyelids while blinking help in distribution of tear film over the cornea, nasolacrimal duct and sensorimotor nerves connecting all these structures. All the components of OSS work synergistically to maintain ocular surface homeostasis and function of OSS is regulated by nervous, endocrine, vascular and immune systems 16 thus disturbance to any part of OSS compromises the normal neural feedback leading to impaired tear film and loss of ocular surface homeostasis. 17, 18 Hyperosmolarity of the tear film, either due to impaired production or increased evaporation of tears, activates inflammatory cascades in the ocular surface tissues which impairs the neural feedback mechanism to the lacrimal gland thus hampering tear production and clearance. 19, 20 Some evidence suggests that dry eye is an immune-based inflammatory disease affecting the ocular surface and lacrimal glands. 21, 22, 23 Clinically, dry eye is confirmed by increased corneal and conjunctival staining, low tear film break up time (TBUT), low Schirmer’s test score and tear hyperosmolarity. 24

DEWS classifies dry eye into two major categories

  1. Evaporative tear deficiency - It is the major primary dry eye disease phenotype. Lipid layer, secreted by meibomian glands, prevents tear evaporation, decreases surface tension and delay TBUT, therefore it is important for stabilization of the tear film. Lipid layer abnormalities leads to more evaporation and increased osmolarity of the tear film. Hyperosmolarity of tear film initiates inflammatory cascades in the ocular surface tissues, nociceptors detect inflammation and send signals to lacrimal glands via autonomic motor signals. The collection of symptoms along with hyperosmolarity of tears, signs of ocular inflammation in a setting of normal or higher than normal rate of aqueous fluid production is defined as evaporative dry eye. It is more commonly seen in women of 45 years or older. 25, 26, 27, 28, 29, 30, 31, 32

  2. Aqueous tear deficiency -It is characterized by decreased volume of tear production by the lacrimal glands. Reduced tear flow leads to hyperosmolarity of tears which initiates inflammatory cascades in the ocular surface tissues. Reduced lacrimal gland secretion can be primary due to any lacrimal gland disease pathology or secondary due to any ocular surface inflammation, which impairs sensory and autonomic secretomotor signals to the lacrimal gland leading to reduced secretion. Lacrimal gland atrophy, seen with CT scan, is age related in both men and women. 29, 33, 34

Mucin layer helps in maintaining moisture in the eye, aqueous layer maintains tear volume as it contains water, electrolytes and protein and lipid layer aids in stabilization of the tear film as it prevents tear evaporation.

Dry eye affects women two to four times more than men and post-menopausal women are more prone to it. 9 Women with some systemic conditions like Sjogren’s syndrome, complete androgen insensitivity syndrome, premature ovarian failure, polycystic ovary syndrome (PCOS) and post-menopausal women using HRT have high prevalence of dry eye disease. 35, 36, 37, 38, 39, 40, 41, 42 Use of androgen antagonists for some prostate conditions in men is a sex specific risk factor for dry eye. 43, 44, 45 This shows that hormonal imbalance play an important role in the pathophysiology of dry eye disease, and gender and sex hormones may play a pivotal role in the etiology of dry eye.

Effects of gonadal hormones on Dry Eye -

Gonadal hormones and the Meibomian gland

Meibomian gland secretes lipid layer of the tear film, decreases surface tension and promotes stabilization of tear film by preventing evaporation of the underlying layer. Meibomian gland dysfunction leads to evaporative dry eye.46 Sex hormones are known to regulate meibomian gland function.45, 47, 48, 49 Androgens have positive impact on meibomian gland function and increases lipid secretion48, 50 while estrogen and progesterone have a negative impact on meibomian gland function and thus decrease lipid secretion.51, 52

Effects of androgen on the meibomian gland

Meibomian gland is the target organ for androgen and is susceptible to effects of androgen. 53, 54 It also explicits mRNA for 5α-reductase enzyme which converts testosterone to its more potent form dihydrotestosterone (DHT).55 Androgen stimulates expression of genes involved in lipid metabolic pathways and thus increases secretion of lipids from the meibomian gland, which forms the lipid layer of the tear film.48, 54 Androgen also suppresses genes associated with keratinization of ductal epithelium, which is thought to be the probable cause of meibomian gland dysfunction, thus it enhances meibomian gland function.52, 56 It's role in regulating the immune system in some studies shows that it imposes trophic effects on the lacrimal and meibomian gland function. 57 Thus androgen deficiency may lead to meibomian gland dysfunction, decreased quality and quantity of meibomian gland lipid layer leading to tear film instability, low tear film break-up time (TBUT) and subsequently evaporative dry eye. These changes are associated with gender and age, and are frequently seen in patients who are not responsive to androgen like women with complete androgen insensitivity syndrome and men with prostate cancer using androgen blockers. This shows the significance of androgen in the regulation of meibomian gland function.38, 39, 43, 45, 58, 59, 60

Genetically lower levels of androgen in women than men and age related decrease in gonadal androgen synthesis in both the sexes may lead to greater risk of dry eye in these populations. 59, 60, 61, 62, 63 In menopausal women, only 30% of the peak androgen level is found. 61, 64 The differences in meibomian gland lipid secretions between men and women may be due to differences in androgen levels between men and women. 59 With age, both sexes show structural and functional changes in the meibomian gland. Acinar cells atrophy and hyper keratinization of ductal epithelium causes more viscosity of the meibomian gland secretions leading to reduced gland function, increased tear film instability and dry eye. 65, 66, 58, 59, 67, 68, 69

A study in orchiedctomized rabbits showed meibomian gland dysfunction due to androgen deficiency which got reversed on administering 19-nortestosterone. 48 Some studies showed that topical testosterone applied to the eyelids improve lipid layer thickness and TBUT and is used in men and women with meibomian gland dysfunction and evaporative dry eye 70, 71 The use of androgen precursor DHEA (Dehydroepiandrosterone) in dry eye patients stimulate the production and release of lipids from the meibomian glands and thus improves signs and symptoms of DED 70, 72 Surprisingly in Sjogren’s syndrome, DHEA couldn’t improve tear production and ocular surface pathology 73, 74 as according to many authors, intracrine conversion of DHEA to testosterone and DHT is suppressed in Sjogren’s syndrome. 75

Effects of estrogen and progesterone on the meibomian gland

Estrogen and progesterone receptors are also present in meibomian gland and these hormones regulate the expression of several genes. The action of estrogen on meibomian gland is opposite to that of androgen. Estrogen inhibits lipid synthesis in meibomian gland and promotes meibomian gland dysfunction and thus causes evaporative dry eye.52 This explains the increased prevalence of dry eye in postmenopausal women using hormone replacement therapy. As studies on mice-show that estrogen effects on sebaceous glands doesn’t occur directly through the interaction with their receptors but indirectly by antagonizing the effect of androgen on sebaceous glands, by blocking their uptake or conversion to more potent form DHT.76, 77 Thus high prevalence of dry eye among women may not be due to increased action of estrogen but due to decreased action of the androgen in women. This also explains high prevalence of DED among post-menopausal women despite the cessation of estradiol synthesis in ovary. Testosterone upregulate the expression of genes involved in meibomian gland lipid synthesis while estrogen downregulate these genes and upregulate those genes which have the opposite effect 51, 52 Progesterone downregulates the expression of genes involved in immune eprocesses but its effect is much less than that of estrogen. 51 A study in mice shows that the sex-related differences in gene expression in the meibomian glands are mainly due to androgen and partly due to estrogen and progesterone.78, 79 Aromatase inhibition in mice leading to estrogen deficiency has no effect on histology of meibomian glands.79 Thus, the sex-related differences in biological processes, molecular functions and cellular components in the meibomian gland could be due to the effects of androgen rather than estrogen and progesterone. 80, 81, 78 More research is required to determine the definitive role of estrogen and progesterone on human meibomian gland and in evaporative dry eye.

Gonadal hormones and the lacrimal gland

Lacrimal gland's basic function is to synthesize and secrete water, proteins and electrolytes, which forms the aqueous layer of the tear film.82, 83 Main and accessory lacrimal glands express genes for androgen and estrogen receptors and through regulation of the transcription of these genes, gonadal hormones control their structure and function.83, 84, 85, 86 Androgens have a positive impact on lacrimal gland tissue and controls their morphology, cellular biology, biochemistry and secretory immune system, as shown in various animal studies, and is responsible for sex-related differences in the lacrimal gland.87, 88 On the other hand, the role of estrogen and progesterone on lacrimal gland tissue is not very conclusive.89, 90

Effects of androgen on the Lacrimal gland

The lacrimal gland is also a target organ for androgens 84 and its structural, functional and pathological characteristics are regulated by androgens 91, 85, 87, 92 and these sex-related differences in androgen influence on lacrimal glands leads to sexual dimorphism in lacrimal gland characteristics, as seen in many animal studies. 91, 92, 93, 94, 95

Lacrimal gland of male rabbit is larger in size than females. 96 Castration of male rats leads to decrease in size of lacrimal glands to that of female rats due to decrease in endogenous androgen. On treating castrated rats and female rats with DHT, there is a change in the characteristics of lacrimal gland to that of intact males. 87, 92 Androgen influences lacrimal gland function by increasing total DNA and protein in the gland and stimulating fluid secretion from the lacrimal gland. 88 Intact male rats synthesize and secrete more immunoglobulin A and glycoprotein from the acinar cells than female or castrated male rats. DHT treatment in castrated rats also stimulates the secretory immune system of the lacrimal gland 92, 93, 96, 97

Primary lacrimal gland deficiency exists in women who have decreased androgen levels such as menopausal women or ovariectomized women or women using oral contraceptives, in spite of their variable estrogen levels. 98, 99, 100 In contrast, men on anti-androgen therapy don’t show changes in their lacrimal gland secretion. 101 This suggests that androgen may have sex-specific action. In autoimmune disease like Sjogren’s syndrome, which is characterized by inflammatory changes in the lacrimal gland leading to aqueous deficient dry eye, reduced levels of androgen have been found.102, 37

The sex-related differences in the effect of androgen on the lacrimal gland is partly due to variations in gene expression. 103, 85, 104, 105, 106, 107 In orchiectomized male and ovariectomized female rats, the number of binding sites and density of androgen receptor proteins are similar in the lacrimal gland 91 but in intact male rats, binding sites and androgen receptor proteins exists in far more numbers than in intact female rats. 84, 102 Androgen use in castrated rats restore the number of androgen receptors and binding sites to that in intact male rats, suggesting that androgens may autoregulate their own binding sites. 102, 108 Use of androgen antagonists or mutations in receptor proteins lead to decreased androgen action and inhibition of transcription and translation of genes. 92, 109, 110 These findings suggest that through alterations in gene activity, androgen action on the lacrimal gland can be regulated.85

Effect of estrogen and progesterone on the lacrimal gland

Effect of estrogen and progesterone on the lacrimal gland has contradictory results. Some human and animal studies suggests that they have proinflammatory role and stimulates autoimmune disease in the lacrimal gland, 111, 112 whereas other studies suggest anti-inflammatory role of these hormones on the lacrimal gland 88, 89, 90 and some studies didn’t find any effect of estrogen on the morphology and function of lacrimal gland. 93, 97, 113, 106, 114, 115, 116, 117, 95

Recent studies show that in ovariectomized rats, there is decreased production and secretion, less TBUT and increased staining of ocular surface117, 118 and administration of estrogen worsen the findings. 119 Estrogen and progesterone increases inflammation and autoimmune diseases in the lacrimal gland. One study in ovariectomized rabbits found that on estrogen treatment, there is an increase in the level of matrix metalloproteinases (MMPs) 2 and 9, a proteolytic enzyme involved in the regulation of inflammatory processes. 120

Some studies suggested that dry eye in postmenopausal women may be due to decreased levels of estrogen and progesterone which causes increased production of proinflammatory cytokines, fibrosis and atrophy of the lacrimal gland.121, 122 Studies in rabbit and mouse models with Sjogren’s syndrome shows that absence of estrogen causes inflammation and regressive changes in the lacrimal gland and estrogen administration causes reversal of these changes, inhibits lymphocyte infiltration and increases fluid production from the lacrimal gland. 123, 90, 112 Estrogen and progesterone influences expression of many immune-related genes and also upregulates the genes that inhibits signaling of pro-inflammatory cytokines.86, 124 This shows that estrogen may have anti-inflammatory role in the lacrimal gland. Aromatase knockout in C57BL/6J mice suggests that estrogen has neither proinflammatory nor anti-inflammatory role.125

In lacrimal gland, estrogen and progesterone antagonize the expression of genes that are stimulated in response to androgen.52 In comparison to androgen, estrogen and progesterone have very little role in the sex-related differences in gene expression and sexual dimorphism of the lacrimal gland, so the aqueous deficient dry eye in women may not be due to them.103, 85, 96, 114, 86 More studies are required in humans to identify the role of estrogen and progesterone on the structure and function of the lacrimal gland and aqueous deficient dry eye.

Gonadal hormones and the ocular surface

Tissues of ocular surface, including cornea, conjunctiva and tear film are likely to be directly affected by gonadal hormones. Mucin layer is secreted mainly by conjunctival goblet cells and its main function is to stabilize the tear film and lubricate and protect the underlying ocular surface.126, 127, 128 Any disturbance in mucin distribution over the ocular surface, due to change in goblet cell density, can lead to tear film instability and dry eye.129, 130, 131, 132, 133, 134, 135

Androgens have an effect on the conjunctival goblet cells and thus regulate mucin production.135, 136 In women during menstruation, the cornea and conjunctiva are affected by physiological changes in the estrogen and progesterone concentrations.137, 138, 139 Estrogen hase negative impact on cornea as high estrogen levels leads to decreased corneal sensitivity and thus leads to dry eye and inflammation of ocular surface. On the other hand, estrogen hase positive impact on the conjunctival epithelium as it enhances maturation of epithelial cells.140

Effects of androgen on the ocular surface

MUC5A is the secretory mucin which is produced by conjunctival goblet cells and MUCs 1,4 and 16 are membrane-associated mucins which are secreted by corneal and conjunctival epithelium and form the inner hydrophilic glycocalyx part of the mucous layer of tear film.141, 142, 143, 144 Women with complete androgen insensitivity syndrome haves reduced levels of MUC5AC and MUC1 protein expression in the mucous layer of tear film, as a result of goblet cell dysfunction rather than decrease in goblet cell number.136, 145

Women with polycystic ovary syndrome (PCOS), despite having hyperandrogenism experience dry eye disease (DED).42, 135 Hyperandrogenism in PCOS leads to goblet cell hyperplasia which leads to mucous hypersecretion but abnormal mucous filaments. These patients have increased MUC5A mRNA expression but reduced levels of MUC5A mucins in the conjunctival tissue and also have increased levels of MUC5AC in their tears, these findings can be attributed to abnormal mucous filaments on the ocular surface of PCOS patients.135 Dry eye in PCOS has shorter TBUT and antiandrogen treatment has been demonstrated to increase TBUT and improves symptoms of dry eye but the side effects of prolonged systemic antiandrogen therapy should also be considered.

Effects of estrogen and progesterone on the ocular surface

Ocular surface tissues are susceptible to estrogen and progesterone levels. Hormonal changes during menstrual cycle, pregnancy, menopause, HRT and OCPs use in females have been linked to structural and functional changes in corneal and conjunctival epithelium, like decrease in corneal sensitivity and change in conjunctival maturation index and can also cause dry eye, affects visual function and leads to development of ocular symptoms.139, 146, 147, 148, 149, 150, 151, 152, 153 These effects in cornea and conjunctiva are due to estrogen and/or progesterone, as testosterone levels remain relatively constant during the menstrual cycle.137, 138, 139, 152

Cornea express receptor for both estrogen and progesterone and these hormones probably reaches cornea from the tear film and aqueous humor. High estrogen levels cause reduced corneal sensitivity and this leads to impaired neural feedback to lacrimal gland for tear production and thus leads to dry eye.149, 152 So, gonadal hormones have an indirect effect on the regulation of structure and function of cornea but their direct effect on cornea in dry eye is not known.

Conjunctival epithelium is sensitive to estrogen as the change in maturation index of its cells correlates with the changes in hormone levels during the menstrual cycle.138 The relative levels of estrogen and progesterone in menstrual, follicular and luteal phase of the menstrual cycle correlate with relative proportions of immature parabasal, mature superficial and intermediate cells respectively.137, 154, 140, 150 Post-menopause, these maturation changes in conjunctival epithelial cells are absent.154, 140 and post-menopausal women have decreased number of goblet cells and are more susceptible to squamous metaplasia and inflammation.129 On giving HRT in post-menopausal women, maturation of conjunctival cells occur and density of goblet cells increases, suggesting that estrogen have an influential effect on the maturation of conjunctival epithelial cells.155, 156

Some studies found that the other signs and symptoms of dry eye like tear turnover, volume, osmolarity and stability doesn’t change despite changes in estrogen and progesterone levels.100, 157 Studies in human corneal epithelial cells also shows that treatment with estrogen upregulates both proinflammatory cytokines and MMPs in the cells, thus an inflammatory component is also present in response to estrogen, which could exacerbate DED.158

A study in ovariectomized mice shows that estrogen and progesterone exposure in ocular surface tissue didn’t affect the distribution and expression of mucin142. In contrast, a study in rabbits shows that estrogen exposure increases mucin secretion from the conjunctival goblet cells but increased progesterone has no effect on mucin secretion.159 This shows the complexity in hormonal regulation of mucin.

Hormonal treatment in Dry eye

Ophthalmic examination in dry eye shows decreased tear production with increased tear film break up time (TBUT), increased tear osmolarity, increased corneal and conjunctival staining, low Schirmer’s test score in aqueous deficient dry eye and decreased levels of lactoferrin and lysozyme in tears.

First line of treatment in dry eye includes lubricating eye drops, second line includes anti-inflammatory drugs like steroid eye drops and immunomodulatory drugs like cyclosporine. In severe cases, punctual occlusion, eyelid corrective surgery, scleral contact lenses and autologous serum tears can be used, depending on the underlying cause.160

Many studies suggest that there might be an important role of hormonal therapy in dry eye treatment, specifically in menopausal women.

Role of HRT in dry eye

Role of HRT in dry eye treatment is inconclusive as some studies show exacerbation of symptoms whereas other studies show improvement of symptoms with HRT and some studies also show no effect of HRT on dry eye. A large population based study on post- menopausal women suggests that women receiving combined estrogen/progesterone HRT or only estrogen containing HRT developed more dry eye signs and symptoms as compared to women not receiving HRT with an odds ratio of 1.29 (prevalence of dry eye in estrogen alone HRT - 69% and estrogen plus progesterone HRT- 29%).161, 162 This also shows that adding progesterone to HRT may have a protective effect in reducing dry eye symptoms.162

In some studies, it has been found that higher doses of HRT (estrogen alone or estrogen plus progesterone) results in higher incidence of dry eyes as compared to lower doses of HRT.163

In contrast, some studies have shown beneficial effects of HRT on dry eye signs and symptoms in post-menopausal women. HRT, in the form of oral and transdermal estrogen and estrogen plus progesterone therapy, reduces dry eye symptoms and have a positive impact on tear production, tear osmolarity and tear film stability.147, 155, 164, 165, 166, 167, 168, 169, 170, 171, 172 Another study showed that topical application of estrogen eye drop and ointment has a beneficial role on tear function, thus improving dry eye symptoms. This shows that local estrogen therapy may be superior to systemic HT in improving dry eye symptoms as systemic HT can’t penetrate the blood- eye barrier, thus hindering its effect on the conjunctivae.172, 173 Duration of HRT also affects the outcome, as one study showed that women taking HRT for > 5 years had less ocular symptoms and increased tear production as compared to women taking HRT for <5 years.167 A significant relationship between HRT and dry eye is yet to be established and larger prospective-controlled studies with long follow-up time are required in this field to reach a definite conclusion.

Role of Androgen treatment in dry eye

Androgens have a crucial role in tear production and have a positive impact on function of meibomian and lacrimal gland.174 Testosterone reduces symptom of dry eye in postmenopausal women175, 176 and in Klinefelter’s syndrome patients177 Patients with complete androgen insensitivity syndrome, men using androgen blockers and women having significantly low testosterone levels have higher chances of dry eye, this shows that androgen deficiency can lead to tear film instability and dysfunction.50 These patients can be benefited by systemic androgen therapy but the undesirable side effects of systemic androgen therapy should also be considered when using in peri- and post-menopausal women. A study in postmenopausal women using Estratest therapy, a combination of methyltestosterone and estrogen, showsed improvement in dry eye symptoms.178 A synthetic steroid hormone, Tibolone, which hase androgenic as well as estrogenic and progestogenic properties, was used in post-menopausal women with Sjogren’s syndrome to treat dry eye. After 3 and 12 months of treatment, it increased Schirmer’s test scores and decreased dry eye symptoms.179 Use of androgen precursors like DHEA in Sjogren’s syndrome patients for 9 months showed no changes in dry eye symptoms.180, 73 A study using depot testosterone in Sjogren’s syndrome patients showed significant improvement in ocular surface inflammation and tear production.181 A recent study in women with low testosterone levels and evaporative dry eye treated with androgen patch showed improvement in Schirmer’s test scores and TBUT after 3 weeks of treatment.182

To prevent the side effects of systemic androgen therapy and to limit systemic absorption of androgen, local androgen treatment modalities like androgen eye drop and transdermal androgen cream has been developed. National Institute of Health found that significant number of dry eye patients become asymptomatic after using testosterone eye drop for 6 months.183 Irritation is common with androgen eye drop due to poor solubility of androgen. To make it more soluble and less irritating, cyclodextrin, a solubilizing compound is used with androgen eye drop and this newer conjugated androgen eye drop yielded positive results in improving dry eye signs and symptoms.174 Some studies also shows that application of testosterone cream to the eyelids significantly reduces dry eye symptoms and normalizes TBUT and lipid layer thickness of the tear film.70, 184 These new local androgen treatment modalities are efficacious and more tolerable to the patient. Studies on dry eye and androgen therapy are limited but most study shows consistent positive relationship between androgen therapy and improvement in dry eye symptoms. Large population based clinical studies are required in this field to determine the benefit of using androgen therapy in dry eye disease.

Candidate selection and Prognosis for hormonal treatment of DED

Age and endogenous hormone levels are the most important factors which should be considered while selecting patients for hormonal treatment of DED.

HRT significantly improves tear production in patients < 50 years old than older patients >50 years and improvement in tear production and age of the patient are negatively correlated.185 In early menopausal period, estrogen may be useful but in later life, systemic and ocular side effects are more common.186 Androgen eye drops are more beneficial in peri- and post-menopausal women than pre-menopausal women.184

Patients with abnormally low endogenous testosterone levels like women with complete androgen insensitivity syndrome, men on androgen blockers and women with abnormally low testosterone levels are most benefitted from systemic and local androgen treatment and shows complete resolution of symptoms after using androgen therapy. 50, 187

Summary

Presence of gonadal hormone receptors, mRNAs and proteins in the meibomian gland, lacrimal gland, conjunctiva and cornea depicts that these tissues are influenced by gonadal hormones. Specific influence on gene expression by gonadal hormones may be the cause of sex- related differences in the structural and functional characteristics of these tissues. Dry eye disease (DED) is a multifactorial immune-mediated inflammatory disease affecting the ocular tissues and gonadal hormones are known to produce effects on the immune system. DED mostly affects women and elderly population and post-menopausal women are more commonly affected. It can be due to low androgen levels in these population as androgen has anti-inflammatory role on the ocular surface. Effects of estrogen and progesterone in dry eye is unclear as dry eye is seen in both high and low estrogen states. It is believed that estrogen and progesterone act indirectly via inhibiting androgen actions on the ocular surface. Recent evidence suggests that imbalances in the levels of testosterone, estrogen and progesterone affects the lacrimal functional unit/OSS, promotes inflammatory processes in them and influences the pathophysiology of dry eye.

HRT therapy, including systemic estrogen or estrogen plus progesterone therapy, have conflicting results on dry eye symptoms, mostly showing no benefit or increasing the symptoms of dry eye. On the other hand, systemic or local androgen therapy shows consistent beneficial effects in dry eye disease. However, more large scale human studies are still needed in this field to determine the effects of gonadal hormones on ocular surface tissues and dry eye disease. It may be possible to develop new therapeutic strategies targeting the pathophysiology of DED through palliation of hormonal imbalances.

Source of Funding

None.

Conflicts of interest

There are no conflicts of interest.

References

1 

The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Work ShopOcul Surf200757592

2 

S McGinnigle SA Naroo F Eperjesi Evaluation of Dry EyeSurv Ophthalmol 201257429331610.1016/j.survophthal.2011.11.003

3 

B Miljanović R Dana DA Sullivan Debra A. Schaumberg Impact of Dry Eye Syndrome on Vision-Related Quality of LifeAm J Ophthalmol200714334091510.1016/j.ajo.2006.11.060

4 

M Uchino DA Schaumberg Dry Eye Disease: Impact on Quality of Life and VisionCurr Ophthalmol Rep20131251710.1007/s40135-013-0009-1

5 

RP Maurya Dry eye disease: An overviewIndian J Clin Exp Ophthalmol2019444334

6 

L Dorennavar RP Maurya VP Singh MK Singh K Sharma R Sharma The role of Rebamipide ophthalmic suspension in management of dry eye diseaseIndian J Clin Exp Ophthalmol201514191610.5958/2395-1451.2015.00025.6

7 

JA Smith The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShopOcul Surf2007593107

8 

DA Schaumberg R Dana JE Buring DA Sullivan Prevalence of dry eye disease among US men: estimates from the Physicians’ Health StudiesArch Ophthalmol20091277638

9 

DA Schaumberg DA Sullivan JE Buring MR Dana Prevalence of dry eye syndrome among US womenAm J Ophthalmol200313623182610.1016/s0002-9394(03)00218-6

10 

DA Schaumberg M Uchino WG Christen RD Semba JE Buring JZ Li Patient Reported Differences in Dry Eye Disease between Men and Women: Impact, Management, and Patient SatisfactionPLoS ONE201389e7612110.1371/journal.pone.0076121

11 

DA Sullivan KM Hammitt DA Schaumberg BD Sullivan CG Begley P Gjorstrup Report of the TFOS/ARVO Symposium on Global Treatments for Dry Eye Disease: An Unmet NeedOcul Surf 20121021081610.1016/j.jtos.2012.02.001

12 

D Dursun D Monroy R Knighton T Tervo M Vesaluoma K Carraway The effects of experimental tear film removal on corneal surface regularity and barrier functionOphthalmology2000107917546010.1016/s0161-6420(00)00273-6

13 

E Goto Y Yagi Y Matsumoto K Tsubota Impaired functional visual acuity of dry eye patientsAm J Ophthalmol20021332181610.1016/s0002-9394(01)01365-4

14 

MA Lemp Report of the National Eye Institute/ Industry workshop on clinical trials in dry eyesEye Contact Lens19952122132

15 

P Rosenthal D Borsook The Corneal Pain System. Part I: The Missing Piece of the Dry Eye PuzzleOcular Surface201210121410.1016/j.jtos.2012.01.002

16 

IK Gipson The Ocular Surface: The Challenge to Enable and Protect VisionInvest Ophthalmol Vis Sci 200748104391810.1167/iovs.07-0770

17 

ME Stern RW Beuerman RI Fox J Gao AK Mircheff SC Pflugfelder The pathology of dry eye: The interaction between the ocular surface and lacrimal glandsCornea1998175849

18 

ME Stern RW Beuerman RI Fox J Gao AK Mircheff SC Pflugfelder A unified theory of the role of the ocular surface in dry eyeAdv Exp Med Biol199843864351

19 

DQ Li L Luo Z Chen HS Kim XJ Song SC Pflugfelder JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cellsExp Eye Res20068258896

20 

L Luo DQ Li A Doshi W Farley RM Corrales SC Pflugfelder Experimental Dry Eye Stimulates Production of Inflammatory Cytokines and MMP-9 and Activates MAPK Signaling Pathways on the Ocular SurfaceInvest Ophthalmol Vis Sci 200445124293430110.1167/iovs.03-1145

21 

S Barabino M Dana Dry eye syndromesChem Immunol Allergy20079217684

22 

SC Pflugfelder Antiinflammatory therapy for dry eyeAm J Ophthalmol200413723374210.1016/j.ajo.2003.10.036

23 

Anti-inflammatory therapy for dry eye. Am J Ophthalmol 2004; 137: 337–342. 23.Research in dry eye: report of the Research Subcommittee of the International Dry Eye Work Shop (2007)Ocul Surf2007517993

24 

AJ Bron Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye Work ShopOcul Surf2007510852

25 

WD Mathers JA Lane Meibomian gland lipids, evaporation, and tear film stabilityAdv Exp Med Biol199843834960

26 

M Guillon C Maissa Tear film evaporation-effect of age and genderCont Lens Anterior Eye20103317175

27 

C Maissa M Guillon Tear film dynamics and lipid layer characteristics- effect of age and genderCont Lens Anterior Eye20103317682

28 

AJ Bron JM Tiffany SM Gouveia N Yokoi LW Voon Functional aspects of the tear film lipid layerExp Eye Res 20047833476010.1016/j.exer.2003.09.019

29 

AJ Bron N Yokoi E Gaffney JM Tiffany Predicted Phenotypes of Dry Eye: Proposed Consequences of Its Natural HistoryOcular Surface200972789210.1016/s1542-0124(12)70299-9

30 

E Knop N Knop T Millar H Obata DA Sullivan The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian GlandInvest Ophthalmol Vis Sci 201152419387810.1167/iovs.10-6997c

31 

MA Lemp LA Crews AJ Bron GN Foulks BD Sullivan Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient CohortCornea2012315472810.1097/ico.0b013e318225415a

32 

CA Blackie DR Korb E Knop R Bedi N Knop EJ Holland Nonobvious Obstructive Meibomian Gland DysfunctionCornea2010291213334510.1097/ico.0b013e3181d4f366

33 

SG Min MS Ha Calculated CT volumes of lacrimal glands in normal Korean orbitsJ Korean Opthalmol Soc20155615

34 

AK Mircheff Y Wang C Ding DW Warren JE Schechter Potentially Pathogenic Immune Cells and Networks in Apparently Healthy Lacrimal GlandsOcular Surface2015131478110.1016/j.jtos.2014.06.003

35 

RP Maurya V Singh A Gupta VP Singh A Kumar A Yadav Dry eye disease associated with Primary Sjogren syndrome: An updateIndian J Clin Exp Ophthalmol2021722596910.18231/j.ijceo.2021.055

36 

DA Sullivan LA Wickham EM Rocha KL Krenzer BD Sullivan R Steagall Androgens and Dry Eye in Sjogren's SyndromeaAnn N Y Acad Sci 19998763122410.1111/j.1749-6632.1999.tb07656.x

37 

D A Sullivan A Belanger J M Cermak R Berube A S Papas R M Sullivan Are women with Sjögren’s syndrome androgen deficient?J Rheumatol20033024139

38 

JM Cermak KL Krenzer RM Sullivan MR Dana DA Sullivan Is Complete Androgen Insensitivity Syndrome Associated with Alterations in the Meibomian Gland and Ocular Surface?Cornea20032265162110.1097/00003226-200308000-00006

39 

BD Sullivan JE Evans JM Cermak KL Krenzer MR Dana DA Sullivan Complete androgen insensitivity syndrome: effect on human meibomian gland secretionsArch Ophthalmol2002120168999

40 

J A Smith S Vitale G F Reed S A Grieshaber L A Goodman V H Vanderhoof Dry eye signs and symptoms in women with premature ovarian failureArch Ophthalmol20041221516

41 

SC Pflugfelder Hormonal Deficiencies and Dry EyeArch Ophthalmol20041222273410.1001/archopht.122.2.273

42 

G F Yavas F Ozturk T Kusbeci S S Ermis M Yilmazer S Cevrioglu Meibomian gland alterations in polycystic ovary syndromeCurr Eye Res2008331338

43 

BD Sullivan JE Evans KL Krenzer RM Dana DA Sullivan Impact of antiandrogen treatment on the fatty acid profile of neutral lipids in human meibomian gland secretionsJ Clin Endocrinol Metab200085486673

44 

RP Maurya VP Singh S Chaudhary M Roy Tanmay Srivastav Prevalence of severe dry eye disease in postmenopausal women in North India: A teaching hospital studyIndian J Obstet Gynecol Res20196194610.18231/2394-2754.2019.0021

45 

KL Krenzer MR Dana MD Ullman JM Cermak DB Tolls JE Evans Effect of Androgen Deficiency on the Human Meibomian Gland and Ocular Surface1J Clin Endocrinol Metab 2000851248748210.1210/jcem.85.12.7072

46 

JP McCulley WE Shine The lipid layer of tears: dependent on meibomian gland functionExp Eye Res2004783361510.1016/s0014-4835(03)00203-3

47 

DA Sullivan EM Rocha MD Ullman KL Krenzer J Gao I Toda Androgen regulation of the meibomian glandAdv Exp Med Biol199843832731

48 

DA Sullivan BD Sullivan MD Ullman EM Rocha KL Krenzer JM Cermak Androgen influence on the meibomian glandInvest Ophthalmol Vis Sci200041373242

49 

D A Sullivan H Yamagami M Liu T Suzuki K L Krenzer J M Cermak Sex steroids, the meibomian gland and evaporative dry eyeCornea200019Supplement 2S12810.1097/00003226-200011002-00187

50 

DA Sullivan BD Sullivan JE Evans F Schirra H Yamagami M Liu Androgen Deficiency, Meibomian Gland Dysfunction, and Evaporative Dry EyeAnn N Y Acad Sci 200296612112210.1111/j.1749-6632.2002.tb04217.x

51 

T Suzuki F Schirra SM Richards RV Jensen DA Sullivan Estrogen and Progesterone Control of Gene Expression in the Mouse Meibomian GlandInvest Ophthalmol Vis Sci 2008495179780810.1167/iovs.07-1458

52 

D A Sullivan R V Jensen T Suzuki S M Richards Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands?Mol Vis200915155372

53 

E M Rocha L A Wickham L A Da Silveira Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissuesBr J Ophthalmol2000847684

54 

H Yamagami F Schirra M Liu SM Richards BD Sullivan DA Sullivan Androgen influence on gene expression in the meibomian glandAdv Exp Med Biol2002506pt A47781

55 

F Schirra T Suzuki DP Dickinson DJ Townsend IK Gipson DA Sullivan Identification of Steroidogenic Enzyme mRNAs in the Human Lacrimal Gland, Meibomian Gland, Cornea, and ConjunctivaCornea20062544384210.1097/01.ico.0000183664.80004.44

56 

H Obata Anatomy and histopathology of human meibomian glandCornea200221704

57 

M Mrugacz N Zywalewska A Bakunowicz-Lazarczyk Neuronal and hormonal regulatory mechanisms of tears production and secretionKlin Oczna200510754850

58 

PJ Driver MA Lemp Meibomian gland dysfunctionSurv Ophthalmol19964053436710.1016/s0039-6257(96)80064-6

59 

B D Sullivan J E Evans M R Dana D A Sullivan Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretionsArch Ophthalmol2006124128692

60 

BD Sullivan JE Evans MR Dana DA Sullivan Impact of androgen deficiency on the lipid profiles in human meibomian gland secretionsAdv Exp Med Biol200250644958

61 

F Labrie A Belanger J Simard LT Van C Labrie DHEA and Peripheral Androgen and Estrogen Formation: IntracrinologyAnn N Y Acad Sci 19957741 Dehydroepiand162810.1111/j.1749-6632.1995.tb17369.x

62 

F Labrie A Bélanger L Cusan JL Gomez B Candas Marked Decline in Serum Concentrations of Adrenal C19 Sex Steroid Precursors and Conjugated Androgen Metabolites During AgingJ Clin Endocrinol Metab 1997828239640210.1210/jcem.82.8.4160

63 

M Guillon C Maïssa Tear film evaporation—Effect of age and genderCont Lens Anterior Eye 2010334171510.1016/j.clae.2010.03.002

64 

F Labrie DHEA, important source of sex steroids in men and even more in womenProg Brain Res201018297148

65 

PG Hykin AJ Bron Age-Related Morphological Changes in Lid Margin and Meibomian Gland AnatomyCornea19921143344210.1097/00003226-199207000-00012

66 

PE Pochi JS Strauss DT Downing Age-related Changes in Sebaceous Gland ActivityJ Invest Dermatol19797311081110.1111/1523-1747.ep12532792

67 

WD Mathers JA Lane MB Zimmerman Tear Film Changes Associated with Normal AgingCornea19961532293410.1097/00003226-199605000-00001

68 

J Shimazaki M Sakata K Tsubota Ocular surface changes and discomfort in patients with meibomian gland dysfunctionArch Ophthalmol1995113126670

69 

M Norn Expressibility of meibomian secretion. Relation to age, lipid precorneal film, scales, foam, hair and pigmentationActa Ophthalmol19876513742

70 

C Worda J Nepp JC Huber MO Sator Treatment of keratoconjunctivitis sicca with topical androgenMaturitas20013732091210.1016/s0378-5122(00)00181-x

71 

RM Schiffman R Bradford B Bunnell F Lai P Bernstein SW Whitcup A multi-center, double-masked, randomized, vehicle-controlled, parallel group study to evaluate the safety and efficacy of testosterone ophthalmic solution in patients with meibomian gland dysfunctionInvest Ophthalmol Vis Sci20064756088

72 

MA Zeligs K Gordon Dehydroepiandrosterone therapy for the treatment of eye disorders. (International Patent) International Publication Number: WO 94/041551994

73 

SR Pillemer MT Brennan V Sankar RA Leakan JA Smith M Grisius Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndromeArthritis Care Res2004514601410.1002/art.20540

74 

A Hartkamp R Geenen GLR Godaert H Bootsma AA Kruize JWJ Bijlsma Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trialAnn Rheum Dis 200867191710.1136/ard.2007.071563

75 

Y T Konttinen V Stegajev A Al-Samadi P Porola J Hietanen M Ainola Sjogren’s syndome and extragonadal sex steroid formation: a clue to a better disease control?J Steroid Biochem Mol Biol201514523744

76 

L. Azzi M El-Alfy F Labrie Gender differences and effects of sex steroids and dehydroepiandrosterone on androgen and oestrogen α receptors in mouse sebaceous glandsBr J Dermatol2006154121710.1111/j.1365-2133.2005.06847.x

77 

G Sansone-Bazzano RM Reisner G Bazzano A Possible Mechanism of Action of Estrogen at the Cellular Level in a Model Sebaceous GlandJ Invest Dermatol 197259429930410.1111/1523-1747.ep12627361

78 

SM Richards H Yamagami F Schirra T Suzuki DA Sullivan RV Jensen Sex-Related Effect on Gene Expression in the Mouse Meibomian GlandCurr Eye Res20063121192810.1080/02713680500514644

79 

RR Darabad T Suzuki SM Richards RV Jensen FA Jakobiec FR Zakka Influence of Aromatase Absence on the Gene Expression and Histology of the Mouse Meibomian GlandInvest Ophthalmol Vis Sci 20135429879810.1167/iovs.12-10992

80 

H Yamagami SM Richards BD Sullivan M Liu RJ Steagall DA Sullivan Gender-associated differences in gene expression of the meibomian glandAdv Exp Med Biol200250645963

81 

H Yamagami F Schirra M Liu SM Richards BD Sullivan DA Sullivan Androgen influence on gene expression in the meibomian glandAdv Exp Med Biol200250647781

82 

DA Dartt Signal transduction and control of lacrimal gland protein secretion: A reviewCurr Eye Res1989866193610.3109/02713688908995762

83 

JL Ubels IK Gipson SJ Spurr-Michaud AS Tisdale RE Van Dyken MP Hatton Gene Expression in Human Accessory Lacrimal Glands of WolfringInvest Ophthalmol Vis Sci 2012531167384710.1167/iovs.12-10750

84 

DA Sullivan JA Edwards LA Wickham JDO Pena J Gao M Ono Identification and endocrine control of sex steroid binding sites in the lacrimal glandCurr Eye Res19961532799110.3109/02713689609007622

85 

SM Richards M Liu RV Jensen F Schirra H Yamagami MJ Lombardi Androgen regulation of gene expression in the mouse lacrimal glandJ Steroid Biochem Mol Biol 20059654011310.1016/j.jsbmb.2005.04.037

86 

T Suzuki F Schirra SM Richards NS Treister MJ Lombardi P Rowley Estrogen’s and Progesterone’s Impact on Gene Expression in the Mouse Lacrimal GlandInvest Ophthalmol Vis Sci 20064711586810.1167/iovs.05-1003

87 

DA Sullivan L Block JDO Pena Influence of androgens and pituitary hormones on the structural profile and secretory activity of the lacrimal glandActa Ophthalmol Scand19967442135

88 

AM Azzarolo AK Mircheff RL Kaswan FZ Stanczyk E Gentschein L Becker Androgen support of lacrimal gland functionEndocrine199761394510.1007/bf02738800

89 

J Pfeilschifter R Köditz M Pfohl H Schatz Changes in Proinflammatory Cytokine Activity after MenopauseEndocrine Rev20022319011910.1210/edrv.23.1.0456

90 

N Ishimaru K Saegusa K Yanagi N Haneji I Saito Y Hayashi Estrogen Deficiency Accelerates Autoimmune Exocrinopathy in Murine Sjögren's Syndrome through Fas-Mediated ApoptosisAm J Pathol 199915511738110.1016/s0002-9440(10)65111-5

91 

DA Sullivan LA Wickham EM Rocha RS Kelleher LA Da Silveira I Toda Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal glandAdv Exp Med Biol19984381142

92 

DA Sullivan KJ Bloch MR Allansmith Hormonal influence on the secretory immune system of the eye: androgen control of secretory component production by the rat exorbital glandImmunology19845223946

93 

DA Sullivan MR Allansmith Hormonal influence on the secretory immune system of the eye: androgen modulation of IgA levels in tears of ratsJ Immunol1985134297882

94 

DA Sullivan Influence of the hypothalamic-pituitary axis on the androgen regulation of the ocular secretory immune systemJ Steroid Biochem19883042933

95 

DA Sullivan KJ Bloch MR Allansmith Hormonal influence on the secretory immune system of the eye: androgen regulation of secretory component levels in rat tearsJ Immunol1984132113035

96 

AM Azzarolo AH Mazaheri AK Mircheff DW Warren Sex-dependent parameters related to electrolyte, water and glycoprotein secretion in rabbit lacrimal glandsCurr Eye Res199312979580210.3109/02713689309020384

97 

DA Sullivan MR Allansmith Hormonal modulation of tear volume in the ratExp Eye Res1986422131910.1016/0014-4835(86)90037-0

98 

WD Mathers D Stovall JA Lane MB Zimmerman S Johnson Menopause and tear function: the influence of prolactin and sex hormones on human tear productionCornea1998173538

99 

P Versura EC Campos Menopause and dry eye. A possible relationshipGynecological Endocrinol20052052899810.1080/09513590400027257

100 

SP Chen G Massaro-Giordano M Pistilli CA Schreiber VY Bunya Tear Osmolarity and Dry Eye Symptoms in Women Using Oral Contraception and Contact LensesCornea2013324423810.1097/ico.0b013e3182662390

101 

DA Sullivan KL Krenzer BD Sullivan DB Tolls I Toda MR Dana Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency?Invest Ophthalmol Vis Sci19994012615

102 

FJ Rocha LA Wickham JDO Pena J Gao M Ono RW Lambert Influence of gender and the endocrine environment on the distribution of androgen receptors in the lacrimal glandJ Steroid Biochem Mol Biol19934667374910.1016/0960-0760(93)90314-m

103 

SM Richards RV Jensen M Liu BD Sullivan MJ Lombardi P Rowley Influence of sex on gene expression in the mouse lacrimal glandExp Eye Res 2006821132310.1016/j.exer.2005.04.014

104 

I Toda LA Wickham DA Sullivan Gender and Androgen Treatment Influence the Expression of Proto-oncogenes and Apoptotic Factors in Lacrimal and Salivary Tissues of MRL/lprMiceClin Immunol Immunopathol1998861597110.1006/clin.1997.4466

105 

J Gao RW Lambert LA Wickham G Banting DA Sullivan Androgen control of secretory component mRNA levels in the rat lacrimal glandJ Steroid Biochem Mol Biol 19955232394910.1016/0960-0760(94)00172-i

106 

J Winderickx I Vercaeren G Verhoeven W Heyns Androgen-dependent expression of cystatin-related protein (CRP) in the exorbital lacrimal gland of the ratJ Steroid Biochem Mol Biol 1994482-31657010.1016/0960-0760(94)90141-4

107 

I Toda BD Sullivan LA Wickham DA Sullivan Gender- and androgen-related influence on the expression of proto-oncogene and apoptotic factor mRNAS in lacrimal glands of autoimmune and non-autoimmune miceJ Steroid Biochem Mol Biol 1999711-2496110.1016/s0960-0760(99)00119-3

108 

M Ono FJ Rocha DA Sullivan Immunocytochemical location and hormonal control of androgen receptors in lacrimal tissues of the female MRL/Mp-Ipr/Ipr mouse model of sjögren's syndromeExp Eye Res19956166596610.1016/s0014-4835(05)80016-8

109 

RW Lambert RS Kelleher LA Wickham JP Vaerman DA Sullivan Neuroendocrinimmune modulation of secretory component production by rat lacrimal, salivary, and intestinal epithelial cellsInvest Ophthalmol Vis Sci 1994351192201

110 

JL Ubels JT Wertz KE Ingersoll RS Jackson II MD Aupperlee Down-regulation of Androgen Receptor Expression and Inhibition of Lacrimal Gland Cell Proliferation by Retinoic AcidExp Eye Res 20027555617110.1006/exer.2002.2054

111 

EH Sato DA Sullivan Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren’s syndromeInvest Ophthalmol Vis Sci199435263242

112 

S Mostafa V Seamon AM Azzarolo Influence of sex hormones and genetic predisposition in Sjögren’s syndrome: A new clue to the immunopathogenesis of dry eye diseaseExp Eye Res 2012961889710.1016/j.exer.2011.12.016

113 

DA Sullivan MR Allansmith Hormonal influence on the secretory immune system of the eye: endocrine interactions in the control of IgA and secretory component levels in tears of ratsImmunology19876033743

114 

AH Cornell-Bell DA Sullivan MR Allansmith Gender-related differences in the morphology of the lacrimal glandInvest Ophthalmol Vis Sci19852611705

115 

D Sullivan R Kelleher J Vaerman L Hann Androgen regulation of secretory component synthesis by lacrimal gland acinar cells in vitroJ Immunol1990145423844

116 

H Vanaken F Claessens I Vercaeren W Heyns B Peeters W Rombauts Androgenic induction of cystatin-related protein and the C3 component of prostatic binding protein in primary cultures from the rat lacrimal glandMol Cell Endocrinol 1996121219720510.1016/0303-7207(96)03866-x

117 

S Singh L Moksha N Sharma JS Titiyal NR Biswas T Velpandian Development and evaluation of animal models for sex steroid deficient dry eyeJ Pharmacol Toxicol Methods 2014701293410.1016/j.vascn.2014.03.004

118 

X Song P Zhao G Wang X Zhao The effects of estrogen and androgen on tear secretion and matrix metalloproteinase-2 expression in lacrimal glands of ovariectomized ratsInvest Ophthalmol Vis Sci20145574551

119 

D Vavilis S Maloutas M Nasioutziki E Boni J Bontis Conjunctiva is an estrogen-sensitive epitheliumActa Obstet Gynecol Scand 1995741079980210.3109/00016349509021200

120 

C Zylberberg V Seamon O Ponomareva K Vellala M Deighan AM Azzarolo Estrogen up-regulation of metalloproteinase-2 and -9 expression in rabbit lacrimal glandsExp Eye Res 20078459607210.1016/j.exer.2007.02.002

121 

S Srinivasan E Joyce M Senchyna T Simpson L Jones Clinical signs and symptoms in post-menopausal females with symptoms of dry eyeOphthalmic Physiol Opt 20082843657210.1111/j.1475-1313.2008.00580.x

122 

H Obata S Yamamoto H Horiuchi R Machinami Histopathologic study of human lacrimal gland. Statistical analysis with special reference to agingOphthalmology199510267886

123 

AM Azzarolo H Eihausen J Schechter Estrogen prevention of lacrimal gland cell death and lymphocytic infiltrationExp Eye Res20037733475410.1016/s0014-4835(03)00120-9

124 

WS Alexander DJ Hilton The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune responseAnnu Rev Immunol20042250329

125 

RR Darabad T Suzuki SM Richards FA Jakobiec FR Zakka S Barabino Does estrogen deficiency cause lacrimal gland inflammation and aqueous-deficient dry eye in mice?Exp Eye Res 20141271536010.1016/j.exer.2014.07.017

126 

IK Gipson Distribution of mucins at the ocular surfaceExp Eye Res20047833798810.1016/s0014-4835(03)00204-5

127 

IK Gipson P Argüeso Role of mucins in the function of the corneal and conjunctival epitheliaInt Rev Cytol Salt Lake City2003149

128 

TJ Millar ST Tragoulias PJ Anderton MS Ball F Miano GR Dennis The Surface Activity of Purified Ocular Mucin at the Air-Liquid Interface and Interactions With Meibomian LipidsCornea20062519110010.1097/01.ico.0000164779.87795.3c

129 

L Rivas MA Oroza A Perez-Esteban J Murube-del-Castillo Morphological changes in ocular surface in dry eyes and other disorders by impression cytologyGraefes Arch Clin Exp Ophthalmol 199223043293410.1007/bf00165940

130 

RA Ralph Conjunctival goblet cell density in normal subjects and in dry eye syndromesInvest Ophthalmol Vis Sci197514299302

131 

JD Nelson JC Wright Conjunctival Goblet Cell Densities in Ocular Surface DiseaseArch Ophthalmol1984102710495110.1001/archopht.1984.01040030851031

132 

P Argueso M Balaram S Spurr-Michaud HT Keutmann MR Dana IK Gipson Decreased levels of the goblet cell mucinMUC5ACin tears of patients with Sjögren syndromeInvest Ophthalmol Vis Sci 200243100411

133 

Y Danjo H Watanabe A S Tisdale M George T Tsumura M B Abelson Alteration of mucin in human conjunctival epithelia in dry eyeInvest Ophthalmol Vis Sci19983926029

134 

JD Nelson VR Havener JD Cameron Cellulose acetate impressions of the ocular surface. Dry eye statesArch Ophthalmol1983101186972

135 

S Bonini F Mantelli C Moretti A Lambiase S Bonini A Micera Itchy-Dry Eye Associated with Polycystic Ovary SyndromeAm J Ophthalmol200714357637110.1016/j.ajo.2007.01.030

136 

F Mantelli C Moretti A Micera S Bonini Conjunctival mucin deficiency in complete androgen insensitivity syndrome (CAIS)Graefes Arch Clin Exp Ophthalmol 2007245689990210.1007/s00417-006-0452-x

137 

P Versura M Fresina EC Campos Ocular surface changes over the menstrual cycle in women with and without dry eyeGynecol Endocrinol 20072373859010.1080/09513590701350390

138 

AM Serrander KE Peek Changes in contact lens comfort related to the menstrual cycle and menopause. A review of articlesJ Am Optom Assoc19936416266

139 

F Feldman J Bain AR Matuk Daily Assessment of Ocular and Hormonal Variables Throughout the Menstrual CycleArch Ophthalmol1978961018353810.1001/archopht.1978.03910060347010

140 

P Kramer V Lubkin W Potter M Jacobs G Labay P Silverman Cyclic Changes in Conjunctival Smears from Menstruating FemalesOphthalmology1990973303710.1016/s0161-6420(90)32588-5

141 

T Inatomi S Spurr-Michaud A S Tisdale Q Zhan S T Feldman I K Gipson Expression of secretory mucin genes by human conjunctival epitheliaInvest Ophthalmol Vis Sci199637168492

142 

C Lange J Fernandez D Shim S Spurr-Michaud A Tisdale IK Gipson Mucin gene expression is not regulated by estrogen and/or progesterone in the ocular surface epithelia of miceExp Eye Res 2003771596810.1016/s0014-4835(03)00064-2

143 

T Inatomi S Spurr-Michaud A S Tisdale I K Gipson Human corneal and conjunctival epithelia express MUC1 mucinInvest Ophthalmol Vis Sci199536181827

144 

IK Gipson Y Hori P Argüeso Character of Ocular Surface Mucins and Their Alteration in Dry Eye DiseaseOcular Surface20042213114810.1016/s1542-0124(12)70149-0

145 

S Mitchell P Abel S Madaan J Jeffs K Chaudhary G Stamp Androgen-Dependent Regulation of Human MUC1 Mucin ExpressionNeoplasia20024191810.1038/sj.neo.7900194

146 

M Millodot The influence of pregnancy on the sensitivity of the cornea.Br J Ophthalmol 19776110646910.1136/bjo.61.10.646

147 

P Affinito AD Spiezio Sardo CD Carlo A Sammartino GA Tommaselli G Bifulco Effects of hormone replacement therapy on ocular function in postmenopauseMenopause2003105482710.1097/01.gme.0000063568.84134.35

148 

PM Kiely LG Carney G Smith Menstrual Cycle Variations of Corneal Topography and ThicknessAm J Optom Physiol Opt 19836010822910.1097/00006324-198310000-00003

149 

B Riss S Binder P Riss P Kemeter Corneal sensitivity during the menstrual cycle.Br J Ophthalmol1982662123610.1136/bjo.66.2.123

150 

NM Guttridge Changes in ocular and visual variables during the menstrual cycleOphthalmic Physiol Opt1994141384810.1111/j.1475-1313.1994.tb00555.x

151 

PS Soni Effects of Oral Contraceptive Steroids on the Thickness of Human CorneaAm J Optom Physiol Opt198057118253410.1097/00006324-198011000-00008

152 

M Millodot A Lamont Influence of menstruation on corneal sensitivity.Br J Ophthalmol 19745887525610.1136/bjo.58.8.752

153 

MM Ward SC Stone CA Sandman Visual perception in women during the menstrual cyclePhysiol Behav 19782032394310.1016/0031-9384(78)90215-9

154 

D Vavilis S Maloutas M Nasioutziki E Boni J Bontis Conjunctiva is an estrogen-sensitive epitheliumActa Obstet Gynecol Scand 1995741079980210.3109/00016349509021200

155 

A Pelit T Bağiş F Kayaselçuk D Dursun Y Akova P Aydin Tear Function Tests and Conjunctival Impression Cytology before and after Hormone Replacement Therapy in Postmenopausal WomenEur J Ophthalmol 20031343374210.1177/112067210301300402

156 

D Vavilis T Agorastos M Vakiani J Jafetas D Panidis T Konstantinidis The effect of transdermal estradiol on the conjunctiva in postmenopausal womenEur J Obstet Gynecol Reprod Biol 199772193610.1016/s0301-2115(97)85911-8

157 

A Tomlinson Effect of oral contraceptives on tear physiologyOphthalmic Physiol Opt 200121191610.1016/s0275-5408(00)00005-3

158 

T Suzuki DA Sullivan Estrogen Stimulation of Proinflammatory Cytokine and Matrix Metalloproteinase Gene Expression in Human Corneal Epithelial CellsCornea20052481004910.1097/01.ico.0000160973.04072.a5

159 

P Aragona D Puzzolo A Micali G Ferreri D Britti Morphological and Morphometric Analysis on the Rabbit Conjunctival Goblet Cells in Different Hormonal ConditionsExp Eye Res 199866181810.1006/exer.1997.0406

160 

MS Milner KA Beckman JI Luchs QB Allen RM Awdeh J Berdahl Dysfunctional tear syndrome: Dry eye disease and associated tear film disorders - New strategies for diagnosis and treatmentCurr Opin Ophthalmol201727147

161 

DA Schaumberg JE Buring DA Sullivan MR Dana Hormone replacement therapy and dry eye syndrome.JAMA200128621149

162 

B Shaharuddin S Ismail-Mokhtar Hussein E Dry eye in post-menopausal Asian women on hormone replacement therapyInt J Ophthalmol2008115860

163 

A AlAwlaqi M Hammadeh Examining the relationship between hormone therapy and dry-eye syndrome in postmenopausal womenMenopause2016235550510.1097/gme.0000000000000570

164 

H Coksuer F Ozcura F Oghan B Haliloglu C Coksuer Effects of estradiol–drospirenone on ocular and nasal functions in postmenopausal womenClimacteric2011144482710.3109/13697137.2010.539724

165 

V Evans T J Miller J A Eden MDP Willcox Menopause, hormone replacement therapy and tear functionAdv Exp Med Biol2002507102933

166 

JH Moon JW Jung KH Shin HJ Paik Effect of hormone replacement therapy on dry eye syndrome in postmenopausal women: a prospective studyJ Korean Ophthalmol Soc2010511759

167 

AA Jensen EJ Higginbotham GM Guzinski IL Davis NJ Ellish A survey of ocular complaints in postmenopausal womenJ Assoc Acad Minor Phys200011439

168 

Ö Altintaş Y Caglar N Yüksel A Demirci L Karabaş The Effects of Menopause and Hormone Replacement Therapy on Quality and Quantity of Tear, Intraocular Pressure and Ocular Blood FlowOphthalmologica20042182120910.1159/000076148

169 

S Guaschino E Grimaldi A Sartore R Mugittu F Mangino P Bortoli Visual function in menopause: the role of hormone replacement therapyMenopause200310537

170 

A Okon´ P Jurowski R Gos´ The influence of the hormonal replacement therapy on the amount and stability of the tear film among peri- and postmenopausal womenKlin Oczna200110317781

171 

M Metka H Enzelsberger W Knogler B Schurz H Aichmair Eye manifestations as climacteric symptomGeburtshilfe Frauenheilkd1991511435

172 

Michael O. Sator Elmar A. Joura Thomas Golaszewski Doris Gruber Peter Frigo Markus Metka Anton Hommer Johannes C. Huber Treatment of menopausal keratoconjunctivitis sicca with topical oestradiolBJOG: An International Journal of Obstetrics and Gynaecology199810511001021470-0328, 1471-052810.1111/j.1471-0528.1998.tb09358.xWileyhttps://dx.doi.org/10.1111/j.1471-0528.1998.tb09358.x

173 

J Akramian A Wedrich J Nepp M Sator Estrogen therapy in keratoconjunctivitis siccaAdv Exp Med Biol199843810051009

174 

T Dawson Testosterone eye drops: A novel treatment for dry eye diseaseOphthalmology Times2015

175 

M Appelmans La ke´rato-conjonctivite se`che de Gougerot-Sjo¨grenArch Ophtalmol (Paris)19488577588

176 

R Bruckner Uber einem erfolgreich mit perandren behandelten fall von Sjogren’schem symptomen complexOphthalmologica19451103742

177 

A Bizzarro G Valentini G Di Martino A DaPonte A De Bellis G Iacono Influence of Testosterone Therapy on Clinical and Immunological Features of Autoimmune Diseases Associated with Klinefelter’s SyndromeJ Clin Endocrinol Metab 198764132610.1210/jcem-64-1-32

178 

G Scott SC Yiu D Wasilewski J Song RE Smith Combined Esterified Estrogen and Methyltestosterone Treatment for Dry Eye Syndrome in Postmenopausal WomenAm J Ophthalmol 2005139611091010.1016/j.ajo.2004.11.042

179 

A Sartore E Grimaldi S Guaschino The treatment of Sjögren's syndrome with tibolone: a case reportAm J Obstet Gynecol 2003189389410.1067/s0002-9378(03)00366-1

180 

H Forsblad-d'Elia H Carlsten F Labrie YT Konttinen C Ohlsson Low Serum Levels of Sex Steroids Are Associated with Disease Characteristics in Primary Sjogren’s Syndrome; Supplementation with Dehydroepiandrosterone Restores the ConcentrationsJ Clin Endocrinol Metab 200994620445110.1210/jc.2009-0106

181 

JM Akudugu JP Slabbert A Serafin L Bohm Frequency of Radiation-Induced Micronuclei in Neuronal Cells Does Not Correlate with Clonogenic SurvivalRadiat Res 2000153162710.1667/0033-7587(2000)153[0062:forimi]2.0.co;2

182 

MA Nanavaty M Long R Malhotra Transdermal androgen patches in evaporative dry eye syndrome with androgen deficiency: a pilot studyBr J Ophthalmol2014984567910.1136/bjophthalmol-2013-304637

183 

A Plc Safety and efficacy study of a testosterone eye drop for the treatment of meibomian gland dysfunction. Clinical trials, National Institute of Health; 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT00755183. Last accessed on 2017 Jun 13].

184 

CG Conner Symptomatic relief of dry eye assessed with the OSDI in patients using 5% testosterone creamInvest Ophthalmol Vis Sci2005462032

185 

Y Feng G Feng S Peng H Li The effects of hormone replacement therapy on dry eye syndromes evaluated by Schirmer test depend on patient ageCont Lens Anterior Eye2016391247

186 

B B Sherwin Estrogen and cognitive aging in womenNeurosci200613810216

187 

J Dach Bioidentical Hormones and Natural Thyroid [Last accessed on 2017 Jun 13].2014http://www.bioidenticalhormones101.com/Dry_Eye_Syndrome15.html



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


  • Article highlights
  • Article tables
  • Article images

Article History

Received : 08-06-2021

Accepted : 14-06-2021

Available online : 27-07-2021


View Article

PDF File   Full Text Article


Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.ijooo.2021.029


Article Metrics






Article Access statistics

Viewed: 475

PDF Downloaded: 130



Wiki in hindi